Advanced searches left 3/3

Gender - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 25 September 2022

* If you want to update the article please login/register

Social Media-Based Treatment: Engaging Sexual and Gender Minority Smokers

Using a portable carbon monoxide measurement device, participants who do not announce no more than 7 days will be required to provide biochemical evidence of smoking status.

Source link: https://clinicaltrials.gov/ct2/show/NCT04461288


Identification of miRNAs Associated With Gender Difference in Osteoarthritis Patients

Some metamorphisms in male patients contribute to the development of OA more than in women, especially in the knee joint. Moreover, new molecular studies shows that in patients with OA, there is a gender-specific activation of PI3K-AKT and hypoxia signaling, indicating the presence of potential gender-specific protein factors that can influence bone metabolism and disease progression. It is likely that sex hormones would function in a predictable manner in the course of OA. Estrogene in women of childbearing age, particularly bone resorption, is inhibiting bone formation, particularly bone resorption; in the post-menopausal period, estrogens are significantly reduced relative to testosterone, favoring the rigidity of the subchondral bone and osteophytes at the joint margins. The response of the male immune system triggered by inflammation of the synovium and synovial fluid in OA is different than in the female counterpart, indicating that there may be differences between the two sexes in joint tissue immunomodulators, including the synovial membrane, synovial fluid, and cartilage itself. Both in molecular terms and inflammatory, as well as differences in the formation and progression of the lymphocyte population involved in the OA-related inflammatory response, are explained by the study's findings. The research is designed to find, characterize, and analyze an expression panel of tissue and circulating miRNAs isolated from patients with both mild and moderate OA, who require prosthetic surgery, in order to be able to identify potential gender-specific biomarkers of disease progression that can be used to monitor the osteointegration process of the prosthetic implant and the post-operative inflammatory response. The biological research requires the collection of samples from patients of both sexes of OA, whether mild or moderate severe, who have undergone endo or arthro-prosthesis surgery, or arthroscopy. Through in vitro studies of cytokine release and ELISA assays, the lymphocyte populations that will display a new phenotype in connection with the disease's aggressiveness will be monitored over time.

Source link: https://clinicaltrials.gov/ct2/show/NCT04851210


Adaptation and Evaluation of a Culturally and Gender Relevant Tobacco Cessation Among Women in Brazil: An Integrated mHealth Approach

We developed and demonstrated the feasibility of a theory-based, culturally- and gender-sensitive Community Health Worker intervention for low-income Brazilian women that extends the public health service's tobacco cessation service. We are developing an integrated CHW-mHealth solution that is culturally and gender-relevant, is theory-based, considers the Brazilian health care system's current design, and is adaptable based on an effective intervention as well as salient features of other mHealth applications that have been shown to be effective in involving customers. In phase II, we'll determine the benefits of the combined CHW-mHealth tobacco cessation program as the unit of randomization. We hypothesize that the women smokers who receive the integrated CHW-mHealth program at 6-months will have a significantly greater 7-day point prevalence abstinence than in the control group, with a significantly higher 7-day point prevalence at 6 months than those who smoke cigarettes.

Source link: https://clinicaltrials.gov/ct2/show/NCT04865276


Comparative Bioavailability Study Between Etoricoxib 90 mg and Tramadol 50 mg, Administered Individually or in Combination, Single Dose in Healthy Subjects of Both Genders Under Fasting Conditions

Etoricoxib 90 mg / Tramadol 50 mg tablets, three treatments, three periods, was the study's objective and longitudinal, truncated, single-dose combination of Etoricoxib 90 mg / Tramadol 50 mg administered orally versus each component administered separately, with three treatments and three periods.

Source link: https://clinicaltrials.gov/ct2/show/NCT05533073


Comparative Effectiveness Research to Improve the Health of Sexual and Gender Minority Patients Through Cultural Competence and Skill Training of Community Health Center Providers and Non-clinical Staff

This project will work with 12 community health centers around the country that have joined and expanded from the HRSA-established Community Health Applied Research Network to determine the most effective way to prepare CHC workers in the collection of SOGI data and analyze the effects of expanded SOGI data collection on LGBT health and wellbeing. Aim 1: Conduct interviews with patients and clinical researchers to discuss how SOGI results are being used to guide patient care and how SOGI results can be used to inform patient care, as well as how patient and clinical researchers research how SOGI data can be collected and used. Compare the effect of a SOGI educational training program to common practice on SOGI documentation rates and LGBT patient screening rates. The initiative will determine the most effective way to prepare CHC workers in the collection of SOGI reports and analyze the impact of enhanced SOGI data collection on LGBT health-related health care will be determined.

Source link: https://clinicaltrials.gov/ct2/show/NCT03554785


A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People ≥ 16 Years of Age Who Have Sex With Male Partners and Are at Risk for HIV Infection

Lenacapavir's main aim of this review is to determine the effectiveness of lenacapavir in reducing the risk of human immunodeficiency virus (HV) infection in relation to the baseline HIV-1 incidence rate. The main aim of this research, which was determined as an ineffective sex killer by lenacapavir in cisgender men, transgender people, transgender people, and gender nonbinary individuals aged 16 to 16 years old have condomless receptive anal sex with partners who have been given male at birth and are at risk of HIV-1bility.

Source link: https://clinicaltrials.gov/ct2/show/NCT04925752

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions